PROCEPT BioRobotics Corporation PRCT
Procept trades at 14x revenue on a false 'all-prostates' TAM; Spruce Point sees channel-stuffing via DSOs at 130 days, no procedure growth, and 30-60% downside to $29-$54.
Thesis
PROCEPT BioRobotics markets its Aquablation system as the future 'treatment for all prostates' for the large BPH market, supporting a $4.7bn market cap and 14x 2025E revenue. Spruce Point's multi-month investigation — spanning urologist interviews, MAUDE adverse-event data, and academic procedure-volume studies — argues the real addressable market is dramatically smaller because minimally-invasive therapies (MISTs) already own 40-45% of BPH surgeries and Aquablation is best suited only for larger prostates (~4% of men over 70 have prostates over 100g). DSOs have ballooned from 47 to 130 days, finished-goods inventory equals 2.6 quarters of handpieces, and Procept failed to pre-announce Q4 results for the first time in four years while CEO Zadno dumped ~$25m of stock. Spruce Point rates PRCT a Strong Sell with a $29-$54 target, implying 30-60% downside.
SCQA
PROCEPT BioRobotics sells the Aquablation robotic resective surgery system for benign prostatic hyperplasia (BPH), with a $4.7bn market cap, pitching itself to investors as the future BPH 'treatment for all prostates'.
Aquablation is only competitive for larger prostates (a tiny ~4% niche), MISTs already capture 40-45% of BPH surgeries, and rising DSOs (47 to 130 days) plus all-time-high inventory suggest channel-stuffing rather than real demand.
Short the stock: Spruce Point rates PRCT a Strong Sell and expects the shares to rerate to mature medical-device peer multiples as growth disappoints and KPI credibility unwinds.
5x-9x 2025E revenue yields a $29-$54 target price range versus the ~$78 unaffected level — approximately 30%-60% long-term downside from current prices.
The three reasons
- 1
Aquablation serves only ~4% of BPH patients (large prostates), not the 'all prostates' TAM pitched
- 2
DSOs ballooned 47 to 130 days; 2.6 quarters of handpiece inventory signals channel-stuffing
- 3
CEO Zadno sold ~$25m of stock; Procept skipped Q4 pre-announcement first time in 4 years
Primary demands
- Short PRCT shares; Spruce Point assigns a Strong Sell opinion
- Investors should discount Procept's 'treatment for all prostates' TAM claim
- Scrutinize Procept's utilization KPI, DSOs, and handpiece inventory as signs of channel-stuffing
- Re-rate Procept to mature medical-device peer multiples (5x-9x 2025E revenue)
KPIs cited
Pattern membership
Precedents cited
- Spruce Point short on TSO3 (2017) — acquired by Stryker at 84% discount
- Spruce Point short on Stryker (2022) — 30% decline post-report
- Spruce Point short on HSKA (2021) — acquired by Mars at 48% discount
- Spruce Point short on Progyny (2023) — shares returned -54% in 2024
Composition what's on the 100 slides
Slide gallery ·
Notes
Classic 100-page Spruce Point short report. Strong SCQA construction with multiple independent attack vectors: TAM overstatement (waterfall chart pg 11), CEO-quote contradictions vs urologist interviews (pg 12), channel-stuffing evidence via DSO/inventory/utilization puzzle pieces (pg 13), peer-multiple rerating (pg 97), and insider-selling tell (pg 14, 96). Cover is a striking AI-generated dental/medical office image — unusual for the genre. Inconsistency: slide 96 refers to 'CEO Radno' while all other slides use 'Zadno' — likely OCR or deck typo; treating correct name as Zadno. Author/signatory not named on cover; firm-authored. Spruce Point's founder is Ben Axler but not credited on the document itself. 'Precedents' are Spruce Point's own short track record (not activist analogies in the traditional sense), used on pg 4 as credibility flex.